Lexeo Therapeutics (LXEO) Equity Average (2022 - 2026)

Lexeo Therapeutics has disclosed Equity Average across 5 years of filings, most recently posting $239.1 million for Q1 2026.

• Equity Average for Q1 2026 came in at $239.1 million, up 133.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $239.1 million (up 133.3% YoY), and the FY2025 annual result was $181.8 million, up 57.79% from the prior year.
• Equity Average came in at $239.1 million for Q1 2026 at Lexeo Therapeutics, up from $183.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $239.1 million in Q1 2026 to a low of -$153.2 million in Q3 2023.
• The 5-year median for Equity Average is $120.6 million (2024), against an average of $59.1 million.
• Across the five-year window, Equity Average surged 619.9% in 2024 and plunged 34.94% in 2025, its largest moves.
• Lexeo Therapeutics' Equity Average stood at -$106.0 million in 2022, then surged by 76.75% to -$24.6 million in 2023, then soared by 619.9% to $128.1 million in 2024, then soared by 43.46% to $183.8 million in 2025, then jumped by 30.11% to $239.1 million in 2026.
• The last three Equity Average figures came in at $239.1 million (Q1 2026), $183.8 million (Q4 2025), and $129.5 million (Q3 2025), per Business Quant data.